The Company previously announced that it submitted the IND amendment to the FDA on November 30, 2022. First Wave BioPharma has been in conversations with FDA and expects a forthcoming response around the end of January
D1sclaimer: I am not a financial advisor or a stock promoter. I am an investor, Period! Do your own DD and make your own investment decisions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.